This article is more than 5 years old. Information may no longer be current.
RIDE/RISE: Ranibizumab outperforms sham for treatment of DME
Ranibizumab improved visual acuity and patient-reported visual function among patients with diabetic macular edema, according to study findings.
Researchers analyzed data from 382 patients in the RIDE study and 377 patients in the RISE study.
In the RIDE study, 128 patients were randomly assigned to receive sham injections, 125 patients received 0.3-mg injections of Lucentis (ranibizumab, Genentech) every 4 weeks and 127 patients received 0.5-mg ranibizumab injections every 4 weeks. In the RISE study, 125 patients were randomly assigned to receive sham injections, 125 patients received 0.3-mg injections of ranibizumab every 4 weeks and 124 patients received 0.5-mg injections every 4 weeks.
Neil M. Bressler
The primary outcome measure was mean change from baseline National Eye Institute Visual Function Questionnaire (NEI VFQ-25) scores at 12 months and 24 months.
Study results showed that for all eyes in both studies, mean NEI VFQ-25 scores improved more in the ranibizumab groups than in the sham treatment groups at 12 and 24 months.
Among better-seeing eyes in the RIDE study, mean change in composite scores in the 0.3-mg ranibizumab group was 10.9 points higher than in the sham treatment group at 24 months.
Among better-seeing eyes in the RISE study, mean change in composite scores was 1.3 points higher in the 0.3-mg ranibizumab group than in the sham group.
Results were similar in the 0.5-mg ranibizumab groups, according to the researchers.
Visual acuity improved more in the ranibizumab groups than in the sham treatment groups among better-seeing eyes and worse-seeing eyes in both studies, according to the researchers.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.